| Literature DB >> 33335235 |
Mohammad Hassan Sohouli1,2, Elham Sharifi-Zahabi1,2, Abolfazl Lari1,2, Somaye Fatahi1,2, Farzad Shidfar3,4.
Abstract
Several randomized clinical trials (RCTs) have investigated the effect of dietary advanced glycation end products (AGE) on obesity factors and related hormones in adults; results were conflicting. Therefore, a study was performed to assess the effect of low advanced glycation end products diet on obesity and related hormones. A comprehensive literature search without any limitation on language was conducted using the following bibliographical databases: Web of Science, Scopus, Ovid MEDLINE, Cochrane, and Embase up to October, 2019. From the eligible trials, 13 articles were selected for the systematic review and meta-analysis. Our systematic reviews and meta-analyses have shown a significant decrease in BMI (WMD: - 0.3 kg/m2; 95% CI: - 0.52, - 0.09, p = 0.005; I2 = 55.8%), weight (WMD: - 0.83 kg; 95% CI: - 1.55, - 0.10, p = 0.026; I2 = 67.0%), and leptin (WMD: - 19.85 ng/ml; 95% CI: - 29.88, - 9.82, p < 0.001; I2 = 81.8%) and an increase in adiponectin (WMD: 5.50 µg/ml; 95% CI: 1.33, 9.67, p = 0.010; I2 = 90.6%) levels after consumption of the low AGE diets compared to the high AGE diets. Also, the effect of intake of low AGE compared to high AGE diets was more pronounced in subgroup with duration > 8 weeks for the BMI and weight. Overall, according to our results, although low AGE diets appeared to be statistically significant in reducing the prevalence of obesity and chronic diseases compared to high consumption of dietary AGEs. But, no clinical significance was observed. Therefore, to confirm these results clinically, further prospective studies should be conducted in this regard. The study protocol was registered in the in International prospective register of systematic reviews (PROSPERO) database as CRD42020203734.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33335235 PMCID: PMC7747626 DOI: 10.1038/s41598-020-79216-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow chart of study selection process.
Included randomized controlled trial study characteristics by population.
| Study ID | Study design | Participants | Sample size | Intervention diet | Control diet | Duration | dAGE content | Outcomes |
|---|---|---|---|---|---|---|---|---|
| Harcourt 2011 | Cross over | Overweight males aged 18–50 years and BMI 26–39 kg/m2) | 11 | LAGE diet | HAGE diet | 2 weeks | HAGE = 14,090, LAGE = 3302 kU AGE/day | BMI |
| Uribarri 2011 | Parallel | Type 2 diabetic patients | 18 randomised, 18 assessed: 12 LAGE & 6 HAGE | LAGE diet | HAGE diet | 4 months | HAGE = > 20, LAGE = < 10 AGE Eq/day | Weight Leptin adiponectin |
| de Courten 2016 | Cross over | Healthy but overweight individuals | 28 randomised, 20 assessed | LAGE diet | HAGE diet | 2 weeks | HAGE = 59, LAGE = 49 mg CML/day | Weight |
| Mark 2014 | Parallel | Overweight women aged 20–50 years | 99 randomised, 74 assessed: 36 LAGE & 37 HAGE diet | LAGE diet | HAGE diet | 4 weeks | HAGE = 24.6, LAGE = 10.7 mg CML/day | BMI Weight WC |
| Macías-Cervantes 2015 | Parallel | Overweight men (BMI > 25 kg/m2) aged 30 to 55 years | 75 randomised, 45 assessed: 15 in the diet plus exercise group, 14 in the exercise group, and 14 in the diet group | LAGE diet | HAGE diet | 12 weeks | HAGE = 13,284 + 4983, LAGE = 13,019 + 4526 kU AGE/day | BMI Weight WC |
| Tantalaki 2014 | Cross over | Polycystic ovary syndrome (PCOS) age range: 18–40 years | 34 randomised, 23 assessed | LAGE diet | HAGE diet | 8 weeks | HAGE = 1869.6 ± 114.6, LAGE = 1869.6 ± 114.6 kU AGE/day | BMI |
| Di Pino 2016 | Parallel | Adults with prediabetes age range between 35 and 65 years; body mass index (BMI) between 18.5 and 40 kg/ m2 | 62 randomised, 57 assessed: 29 LAGE & 28 HAGE diet | LAGE diet | HAGE diet | 24 weeks | N/A | BMI |
| Vlassara 2016 | Parallel | Obese subjects with metabolic syndrome aged 50 years or above | 138 randomised, 100 assessed: 51 in LAGE & 49 HAGE | LAGE diet | HAGE diet | 48 weeks | HAGE = 20 + 11, LAGE = 7 + 6 AGE Eq/day | BMI Weight WC Leptin adiponectin |
| Cai 2004 | Parallel | Diabetic patients with normal lipid profile & renal function | 24 randomised: 11 HAGE & 13 LAGE | LAGE diet | HAGE diet | 6 weeks | HAGE = 5 times higher than LAGE | BMI |
| Vlassara 2002 | Parallel | Diabetic subjects with good glycemic control and normal renal function | 11 for cross over and 13 for parallel trials (6 in high and 7 in low AGE diet) | LAGE diet | HAGE diet | 6 weeks | HAGE = 5 times higher than LAGE | weight |
| Baye 2017 | cross over | Overweight and obese otherwise healthy adults | 204 randomised: 11 HAGE & 13 LAGE | LAGE diet | HAGE diet | 2 weeks | HAGE = 3 times higher than LAGE | BMI weight |
| Yacoub2017 | Parallel | Healthy adults aged 50–69 years | 20 randomised, 20 assessed: 10 in each group | LAGE diet | HAGE diet | 6 weeks | HAGE = 26.96 , LAGE = 26.18 AGE Eq/day | BMI |
| Uribarri 2014 | Parallel | Healthy participants over the age of 60 | 18 randomised, 18 assessed: 10 LAGE & 6 HAGE | LAGE diet | HAGE diet | 16 weeks | HAGE = > 15, LAGE = < 10 AGE Eq/day | BMI Leptin adiponectin |
WC; Waist circumference; BMI; Body mass index.
Risk of bias assessment according to the Cochrane collaboration’s risk of bias assessment tool.
| Study, Year (reference) | Random sequence generation | Allocation concealment | Blinding of participant and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Overall assessment of risk of bias |
|---|---|---|---|---|---|---|---|
| Harcourt 2011 | Unclear | Unclear | Unclear | Unclear | Low | Low | Unclear |
| Uribarri 2011 | Low | Unclear | Unclear | Low | Low | Low | Unclear |
| de Courten 2016 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear |
| Mark 2014 | Low | Unclear | Unclear | Unclear | Low | Low | Unclear |
| Macías-Cervantes 2015 | Low | Unclear | Low | Low | Low | Unclear | Unclear |
| Tantalaki 2014 | Low | Low | Unclear | Low | Low | Low | Unclear |
| Di Pino 2016 | Unclear | Unclear | Unclear | Unclear | Low | Low | Unclear |
| Vlassara 201(28) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear |
| Cai 2004(13) | Low | Low | Unclear | Low | Unclear | Low | Unclear |
| Vlassara 2002 | Low | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear |
| Baye 2017 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear |
| Yacoub 2017 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear |
| Uribarri 2014 | High | High | Unclear | Unclear | Unclear | Low | High |
Figure 2Forest plot of randomized controlled trials investigating the effects of low dietary AGEs on BMI.
Figure 3Forest plot of randomized controlled trials investigating the effects of low dietary AGEs on weight.
Figure 4Forest plot of randomized controlled trials investigating the effects of low dietary AGEs on WC.
Figure 5Forest plot of randomized controlled trials investigating the effects of low dietary AGEs on leptin level.
Figure 6Forest plot of randomized controlled trials investigating the effects of low dietary AGEs on adiponectin level.